Cited by 390Adipokines, Inflammation, and Metabolic DiseasesBlood Coagulation and Thrombosis MechanismsCardiovascular Disease and Adiposity

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences

Alessi, Marie-Christine, Juhan-Vague, Irène·2006·Arteriosclerosis, Thrombosis, and Vascular Biology

DOI 10.1161/01.atv.0000242905.41404.68

Open this paper in CoChat — free account

Abstract

The link between plasminogen activator inhibitor (PAI)-1 and the metabolic syndrome with obesity was established many years ago. Increased PAI-1 level can be now considered a true component of the syndrome. The metabolic syndrome is associated with an increased risk of developing cardiovascular disease, and PAI-1 overexpression may participate in this process. The mechanisms of PAI-1 overexpression during obesity are complex, and it is conceivable that several inducers are involved at the same time at several sites of synthesis. Interestingly, recent in vitro and in vivo studies showed that besides its role in atherothrombosis, PAI-1 is also implicated in adipose tissue development and in the control of insulin signaling in adipocytes. These findings suggest PAI-1 inhibitors serve in the control of atherothrombosis and insulin resistance.

Integrity signals

Registry

Crossref · 10.1161/01.atv.0000242905.41404.68

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
The metabolic syndrome
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
The metabolic syndrome
Eckel, R. H., Grundy, S. M., & Zimmet, P. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,755
Increased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508
Obesity and Metabolic Syndrome in Circadian Clock Mutant Mice
Turek, F. W., Joshu, C., Kohsaka, A., Lin, E., Ivanova, G., McDearmon, E., Laposky, A., Losee-Olson, S., Easton, A., Jensen, D. R., et al. (2005) · Science · doi:10.1126/science.1108750 · Cited by 2,485
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J. B., Ferrannini, E., & Stern, M. P. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,400
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270
Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults
Malik, S., Wong, N. D., Franklin, S. S., Kamath, T. V., L'Italien, G. J., Pio, J. R., & Williams, G. R. (2004) · Circulation · doi:10.1161/01.cir.0000140677.20606.0e · Cited by 1,837
Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris
Thompson, S. G., Kienast, J., Pyke, S., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,819
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766
Comparison of the Release of Adipokines by Adipose Tissue, Adipose Tissue Matrix, and Adipocytes from Visceral and Subcutaneous Abdominal Adipose Tissues of Obese Humans
Fain, J. N., Madan, A. K., Hiler, M. L., Cheema, P. S., & Bahouth, S. W. (2004) · Endocrinology · doi:10.1210/en.2003-1336 · Cited by 1,619
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., de Faire, U., Dahlén, G. H., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction
Boden, G., & Shulman, G. I. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.3.x · Cited by 1,300
Reduction of Macrophage Infiltration and Chemoattractant Gene Expression Changes in White Adipose Tissue of Morbidly Obese Subjects After Surgery-Induced Weight Loss
Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C., Coupaye, M., Pelloux, V., Hugol, D., Bouillot, J.-L., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2277 · Cited by 1,164
Prevalence of the Metabolic Syndrome and Its Relation to All-Cause and Cardiovascular Mortality in Nondiabetic European Men and Women
Hu, G. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1066 · Cited by 1,135
BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis
Rudic, R. D., McNamara, P., Curtis, A.-M., Boston, R. C., Panda, S., Hogenesch, J. B., & FitzGerald, G. A. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020377 · Cited by 1,059
Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes
Festa, A., D’Agostino, R., Tracy, R. P., & Haffner, S. M. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1131 · Cited by 1,057
Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty
Shimomura, I., Funahasm, T., Takahashi, M., Maeda, K., Kotani, K., Nakamura, T., Yamashita, S., Miura, M., Fukuda, Y., Takemura, K., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-800 · Cited by 889
11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress
Kotelevtsev, Y. V., Holmes, M. C., Burchell, A. N., Houston, P., Schmoll, D., Jamieson, P. M., Best, R., Brown, R., Edwards, C. R. W., Seckl, J. R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14924 · Cited by 863
Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease
Kohler, H. P., & Grant, P. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422406 · Cited by 805
The role of TNFα and TNF receptors in obesity and insulin resistance
Hotamisligil, G. S. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00490.x · Cited by 780
Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease
Alessi, M., Peiretti, F., Morange, P., Henry, M., Nalbone, G., & Juhan-Vague, I. (1997) · Diabetes · doi:10.2337/diab.46.5.860 · Cited by 614
Self-citation
High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor
Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G. (1998) · Circulation · doi:10.1161/01.cir.98.21.2241 · Cited by 602
Non–Insulin-Dependent Diabetes Mellitus and Fasting Glucose and Insulin Concentrations Are Associated With Arterial Stiffness Indexes
Salomaa, V. V., Riley, W. A., Kark, J. D., Nardo, C. J., & Folsom, A. R. (1995) · Circulation · doi:10.1161/01.cir.91.5.1432 · Cited by 580
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
Juhan-Vague, I., Alessi, M., & Vague, P. (1991) · Diabetologia · doi:10.1007/bf00403280 · Cited by 566
Self-citation
FOXC2 Is a Winged Helix Gene that Counteracts Obesity, Hypertriglyceridemia, and Diet-Induced Insulin Resistance
Cederberg, A., Grønning, L. M., Åhrén, B., Taskén, K., Carlsson, P., & Enerbäck, S. (2001) · Cell · doi:10.1016/s0092-8674(01)00474-3 · Cited by 557
Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris
Juhan-Vague, I., Pyke, S., Alessi, M., Jespersen, J., Haverkate, F., & Thompson, S. G. (1996) · Circulation · doi:10.1161/01.cir.94.9.2057 · Cited by 551
Self-citation
Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.
Vaughan, D. E., Lazos, S. A., & Tong, K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117809 · Cited by 528
Increased Fat Intake, Impaired Fat Oxidation, and Failure of Fat Cell Proliferation Result in Ectopic Fat Storage, Insulin Resistance, and Type 2 Diabetes Mellitus
Ravussin, É., & Smith, S. R. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04292.x · Cited by 466
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects
Vague, P., Juhan-Vague, I., Aillaud, M. F., Badier, C., Viard, R., Alessi, M., & Collen, D. (1986) · Metabolism · doi:10.1016/0026-0495(86)90209-x · Cited by 443
Self-citation
Clustering of Procoagulation, Inflammation, and Fibrinolysis Variables with Metabolic Factors in Insulin Resistance Syndrome
Sakkinen, P. A., WAHL, P. W., Cushman, M., Lewis, M. R., & Tracy, R. P. (2000) · American Journal of Epidemiology · doi:10.1093/aje/152.10.897 · Cited by 420
Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1
Ma, L.-J., Mao, S.-L., Taylor, K. L., Kanjanabuch, T., Guan, Y., Zhang, Y.-H., Brown, N. J., Swift, L. L., McGuinness, O. P., Wasserman, D. H., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.2.336 · Cited by 404
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
Juhan-Vague, I., Alessi, M.-C., Mavri, A., & Morange, P. E. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00279.x · Cited by 371
Self-citation
11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice
Hermanowski‐Vosatka, A., Balkovec, J. M., Cheng, K., Chen, H. Y., Hernandez, M., Koo, G. C., LeGrand, C. B., Li, Z., Metzger, J. M., Mundt, S. S., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050119 · Cited by 361
Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.
Alessi, M. C., Bastelica, D., Morange, P., Berthet, B., Leduc, I., Verdier, M., Geel, O., & Juhan-Vague, I. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1374 · Cited by 344
Self-citation
Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.
Dawson, S. J., Hamsten, A., Wiman, B., HENNEY, A. M., & Humphries, S. E. (1991) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.11.1.183 · Cited by 316
Pleiotropic functions of plasminogen activator inhibitor-1
LIJNEN, H. R. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00827.x · Cited by 313
Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.
Kerins, D. M., Hao, Q., & Vaughan, D. E. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118312 · Cited by 304
Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1
Skurk, T., & Hauner, H. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802778 · Cited by 303
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.
Samad, F., Yamamoto, K., & Loskutoff, D. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118404 · Cited by 301
Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.
Stiko, A., Wiman, B., Hamsten, A., & Nilsson, J. (1990) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.10.6.1067 · Cited by 295
Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2
Alessi, M., Juhan-Vague, I., Kooistra, T., Declerck, P. J., & Collen, D. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646997 · Cited by 289
Self-citation
Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease
Anand, S. S., Yi, Q., Gerstein, H. C., Lonn, E., Jacobs, R., Vuksan, V., Teo, K. K., Davis, B. C., Montague, P., & Yusuf, S. (2003) · Circulation · doi:10.1161/01.cir.0000080884.27358.49 · Cited by 285
Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease
Dellas, C., & Loskutoff, D. J. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0033 · Cited by 285
Increased Plasminogen Activator Inhibitor Type 1 in Coronary Artery Atherectomy Specimens From Type 2 Diabetic Compared With Nondiabetic Patients
Sobel, B. E., Woodcock‐Mitchell, J., Schneider, D. J., Holt, R. E., Marutsuka, K., & Gold, H. K. (1998) · Circulation · doi:10.1161/01.cir.97.22.2213 · Cited by 270
Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1
Brown, N. J., Ağırbaşlı, M. A., Williams, G. H., Litchfield, W. R., & Vaughan, D. E. (1998) · Hypertension · doi:10.1161/01.hyp.32.6.965 · Cited by 269
Insulin Inhibits the Pro-Inflammatory Transcription Factor Early Growth Response Gene-1 (Egr)-1 Expression in Mononuclear Cells (MNC) and Reduces Plasma Tissue Factor (TF) and Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations
Aljada, A., Ghanim, H., Mohanty, P., Kapur, N., & Dandona, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8462 · Cited by 267
Fat as an Endocrine Organ: Relationship to the Metabolic Syndrome
Hutley, L. J., & Prins, J. B. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200512000-00005 · Cited by 265
Which Hemostatic Markers Add to the Predictive Value of Conventional Risk Factors for Coronary Heart Disease and Ischemic Stroke?
Smith, A. D., Patterson, C., Yarnell, J., Rumley, A., Ben‐Shlomo, Y., & Lowe, G. D. O. (2005) · Circulation · doi:10.1161/circulationaha.105.557132 · Cited by 256
Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes
Chen, B., Lam, K. S. L., Wang, Y., Wu, D., Lam, M. C., Shen, J., Wong, L., Hoo, R. L. C., Zhang, J., & Xu, A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.004 · Cited by 238
Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-α
Wang, B., Jenkins, J. R., & Trayhurn, P. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00475.2004 · Cited by 235
Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
Eriksson, P. O., Reynisdottir, S., Lönnqvist, F., Stemme, V., Hamsten, A., & Arner, P. (1998) · Diabetologia · doi:10.1007/s001250050868 · Cited by 228
Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1
Samad, F., Uysal, K. T., Wiesbrock, S. M., Pandey, M., Hotamisligil, G. S., & Loskutoff, D. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6902 · Cited by 226
Elaboration of Type-1 Plasminogen Activator Inhibitor From Adipocytes
Lundgren, C. H., Brown, S. L., Nordt, T. K., Sobel, B. E., & Fujii, S. (1996) · Circulation · doi:10.1161/01.cir.93.1.106 · Cited by 224
Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults.
Folsom, A. R., Qamhieh, H. T., Wing, R. R., Jeffery, R. W., Stinson, V., Kuller, L. H., & Wu, K. K. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.2.162 · Cited by 224
Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.
Juhan-Vague, I., Alessi, M., Joly, P., Thirion, X., Vague, P., Declerck, P. J., Serradimigni, A., & Collen, D. (1989) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.9.3.362 · Cited by 201
Self-citation
Stromal Cells Are the Main Plasminogen Activator Inhibitor-1-Producing Cells in Human Fat
Bastelica, D., Morange, P., Berthet, B., Borghi, H., Paulmyer‐Lacroix, O., Grino, M., Juhan-Vague, I., & Alessi, M. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0102.101552 · Cited by 190
Self-citation
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska, Y. T., Yu, J., Olefsky, J. M., & Sobel, B. E. (2000) · Diabetes · doi:10.2337/diabetes.49.4.633 · Cited by 184
Hemostatic Markers of Endothelial Dysfunction and Risk of Incident Type 2 Diabetes
Meigs, J. B., O’Donnell, C. J., Tofler, G. H., Benjamin, E. J., Fox, C. S., Lipinska, I., Nathan, D. M., SULLIVAN, L. M., D’Agostino, R. B., & Wilson, P. W. F. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1041 · Cited by 184
1 Mechanisms of physiological fibrinolysis
LIJNEN, H. R., & Collen, D. (1995) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(05)80268-9 · Cited by 183
Plasminogen Activator Inhibitor 1: Biosynthesis and mRNA Level Are Increased by Insulin in Cultured Human Hepatocytes
Kooistra, T., Bosma, P. J., Töns, H. A. M., van den Berg, A. P., Meyer, P., & Princen, H. M. G. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646891 · Cited by 182
Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation
Alessi, M., Bastelica, D., Mavri, A., Morange, P., Berthet, B., Grino, M., & Juhan-Vague, I. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000077401.36885.bb · Cited by 178
Self-citation
Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome
Mertens, I. L., Verrijken, A., Michiels, J. J., van der Planken, M., Ruige, J. B., & Gaal, L. F. V. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803189 · Cited by 176
Disruption of the plasminogen activator inhibitor‐1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice
Schäfer, K., Fujisawa, K., Konstantinides, S., & Loskutoff, D. J. (2001) · The FASEB Journal · doi:10.1096/fj.00-0750fje · Cited by 174
Increased Plasminogen Activator Inhibitor-1 and Vasculopathy
Sobel, B. E. (1999) · Circulation · doi:10.1161/01.cir.99.19.2496 · Cited by 159
Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality
Collet, J., Montalescot, G., Vicaut, É., Ankri, A., Walylo, F., Lesty, C., Choussat, R., Beygui, F., Borentain, M., Vignolles, N., et al. (2003) · Circulation · doi:10.1161/01.cir.0000083471.33820.3c · Cited by 158
Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2
Schoenhard, J. A. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(03)00051-8 · Cited by 157
Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects
Pandolfi, A., Cetrullo, D., Polishuck, R. S., Alberta, M. M., Calafiore, A., Pellegrini, G., Vitacolonna, E., Capani, F., & Consoli, A. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0801.093667 · Cited by 156
Angiotensin II and Its Metabolites Stimulate PAI-1 Protein Release From Human Adipocytes in Primary Culture
Skurk, T., Lee, Y., & Hauner, H. (2001) · Hypertension · doi:10.1161/01.hyp.37.5.1336 · Cited by 150
Progression of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in Relation to Incident Type 2 Diabetes
Festa, A., Williams, K., Tracy, R. P., Wagenknecht, L. E., & Haffner, S. M. (2006) · Circulation · doi:10.1161/circulationaha.106.616177 · Cited by 147
Visceral Fat Accumulation and Its Relation to Plasma Hemostatic Factors in Healthy Men
CIGOLINI, M., Targher, G., Andreis, I. A. B., Tonoli, M., Agostino, G., & Sandre, G. D. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.3.368 · Cited by 141
Plasminogen activator inhibitor-1 modulates adipocyte differentiation
Liang, X., Kanjanabuch, T., Mao, S.-L., Hao, C., Tang, Y., Declerck, P. J., Hasty, A. H., Wasserman, D. H., Fogo, A. B., & Ma, L.-J. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00605.2004 · Cited by 136
Influence of PAI-1 on Adipose Tissue Growth and Metabolic Parameters in a Murine Model of Diet-Induced Obesity
Morange, P., LIJNEN, H. R., Alessi, M., Kopp, F., Collen, D., & Juhan-Vague, I. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.4.1150 · Cited by 130
Self-citation
Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women
Vague, P., Juhan-Vague, I., Chabert, V., Alessi, M., & Atlan, C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90241-2 · Cited by 126
Self-citation
Stimulation by Proinsulin of Expression of Plasminogen Activator Inhibitor Type-I in Endothelial Cells
Schneider, D. J., Nordt, T. K., & Sobel, B. E. (1992) · Diabetes · doi:10.2337/diab.41.7.890 · Cited by 124
Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma Concentrations
Henry, M., Trégouët, D., Alessi, M., Aillaud, M. F., Visvikis‐Siest, S., Siest, G., Tiret, L., & Juhan-Vague, I. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.1.84 · Cited by 121
Self-citation
Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.
Morange, P., Aubert, J., Peiretti, F., LIJNEN, H. R., Vague, P., Verdier, M., Négrel, R., Juhan-Vague, I., & Alessi, M. (1999) · Diabetes · doi:10.2337/diabetes.48.4.890 · Cited by 115
Self-citation
Intramural Plasminogen Activator Inhibitor Type-1 and Coronary Atherosclerosis
Sobel, B. E., Taatjes, D. J., & Schneider, D. J. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000091250.53231.4d · Cited by 112
Hormonal Control of Plasminogen Activator Inhibitor-1 Gene Expression and Production in Human Adipose Tissue: Stimulation by Glucocorticoids and Inhibition by Catecholamines
Halleux, C. M., Declerck, P. J., Tran, S. L., Détry, R., & Brichard, S. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6127 · Cited by 110
Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women
Janand-Delenne, B., Chagnaud, C., Raccah, D., Alessi, M., Juhan-Vague, I., & Vague, P. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800585 · Cited by 103
Self-citation
Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system
Kulla, A., Simisker, A., Sirén, V., Lawrence, D. A., Asser, T., Vaheri, A. I., & Teesalu, T. (2004) · Thrombosis and Haemostasis · doi:10.1160/th02-12-0310 · Cited by 95
Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1
LIJNEN, H. R., Maquoi, E., Morange, P., Vörös, G., HOEF, B. V., Kopp, F., Collen, D., Juhan-Vague, I., & Alessi, M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000044457.60665.dd · Cited by 94
Self-citation
Unsaturated Fatty Acids Increase Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells
Nilsson, L., Banfi, C., Diczfalusy, U., Tremoli, E., Hamsten, A., & Eriksson, P. O. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.11.1679 · Cited by 94
Inflammatory Cytokines Interleukin-6 and Oncostatin M Induce Plasminogen Activator Inhibitor-1 in Human Adipose Tissue
Rega‐Kaun, G., Kaun, C., Weiss, T. W., Demyanets, S., Zorn, G., Kastl, S., Steiner, S., Seidinger, D., Kopp, C. W., Frey, M., et al. (2005) · Circulation · doi:10.1161/01.cir.0000161823.55935.be · Cited by 91
The common -675 4G/5G polymorphism in the plasminogen activator inhibitor –1 gene is strongly associated with obesity
Hoffstedt, J., Andersson, I., Persson, L., Isaksson, B., & Arner, P. (2002) · Diabetologia · doi:10.1007/s00125-001-0774-5 · Cited by 90
Adipocytokines and Incident Diabetes Mellitus in Older Adults
Kanaya, A. M., Fyr, C. W., Vittinghoff, E., Harris, T. B., Park, S. W., Goodpaster, B. H., Tylavsky, F., & Cummings, S. R. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.350 · Cited by 87
Molecular mechanisms of tumor necrosis factor‐α‐mediated plasminogen activator inhibitor‐1 expression in adipocytes
Pandey, M., Loskutoff, D. J., & Samad, F. (2005) · The FASEB Journal · doi:10.1096/fj.04-3459fje · Cited by 84
Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes
Trost, S. U., Pratley, R. E., & Sobel, B. E. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0052-5 · Cited by 81
Insulin-Like Growth Factor Binding Protein-5 Binds to Plasminogen Activator Inhibitor-I*
Nam, T., Busby, W. H., & Clemmons, D. R. (1997) · Endocrinology · doi:10.1210/endo.138.7.5230 · Cited by 79
Short-Term Infusions of Insulin, Triacylglycerol and Glucose do not Cause Acute Increases in Plasminogen Activator Inhibitor-1 Concentrations in Man
Grant, P. J., Kruithof, E. K. O., Felley, C. P., Felber, J. P., & Bachmann, F. (1990) · Clinical Science · doi:10.1042/cs0790513 · Cited by 72
PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population
Lopes, C., Christian Dina, C., Durand, E., & Froguel, P. (2003) · Diabetologia · doi:10.1007/s00125-003-1170-0 · Cited by 68
Expression Profiling Identifies Genes That Continue to Respond to Insulin in Adipocytes Made Insulin-resistant by Treatment with Tumor Necrosis Factor-α
Sartipy, P., & Loskutoff, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306922200 · Cited by 67
Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function
Båvenholm, P. (1998) · European Heart Journal · doi:10.1053/euhj.1997.0752 · Cited by 67
Plasminogen activator inhibitor type‐1 inhibits insulin signaling by competing with αvβ3 integrin for vitronectin binding
López‐Alemany, R., Redondo, J. M., Nagamine, Y., & Muñoz‐Cánoves, P. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03453.x · Cited by 65
Inflammation, thrombosis and atherosclerosis: results of the Glostrup study
de Maat, M. P. M., Bladbjerg, E., Drivsholm, T., Borch-Johnsen, K., Møller, L., & Jespersen, J. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00213.x · Cited by 65
On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice
LIJNEN, H. R., Alessi, M., HOEF, B. V., Collen, D., & Juhan-Vague, I. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01390.x · Cited by 64
Self-citation
Cell Adhesion and Focal Adhesion Kinase Regulate Insulin Receptor Substrate-1 Expression
Lebrun, P., Baron, V. T., Hauck, C. R., Schlaepfer, D. D., & OBBERGHEN, E. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006162200 · Cited by 62
Very Low Density Lipoprotein–Mediated Signal Transduction and Plasminogen Activator Inhibitor Type 1 in Cultured HepG2 Cells
Banfi, C., Mussoni, L., Risé, P., Cattaneo, M. G., Vicentini, L. M., Battaini, F., Galli, C., & Tremoli, E. (1999) · Circulation Research · doi:10.1161/01.res.85.2.208 · Cited by 60
The plasminogen activator inhibitor-1 −675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study
Juhan-Vague, I., Morange, P., Frère, C., Aillaud, M. F., Alessi, M., Hawe, E., Boquist, S., Tornvall, P., Yudkin, J. S., Tremoli, E., et al. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00458.x · Cited by 59
Self-citation
Synthesis and Secretion of Plasminogen Activator Inhibitor-1 by Human Preadipocytes
Crandall, D. L., Quinet, E. M., Morgan, G. A., Busler, D. E., McHendry‐Rinde, B., & Kral, J. G. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.5987 · Cited by 59
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-α, TNF-α converting enzyme and ADAMTS family members in murine fat territories
Vörös, G., Maquoi, E., Collen, D., & LIJNEN, H. R. (2003) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(02)00589-4 · Cited by 54
Thiazolidinediones inhibit TNFα induction of PAI-1 independent of PPARγ activation
Liu, H. B., Hu, Y., Medcalf, R. L., Simpson, R. W., & Dear, A. E. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.055 · Cited by 47
Divergent Roles for p55 and p75 TNF-α Receptors in the Induction of Plasminogen Activator Inhibitor-1
Pandey, M., Tuncman, G., Hotamışlıgil, G. S., & Samad, F. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63888-6 · Cited by 43
The Coagulation and Fibrinolytic Responses of Baboons after In Vivo Thrombin Generation – Effect of Interleukin 6
Kruithof, E. K. O., Mestries, J. C., Gascon, M.-P., & Ythier, A. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656076 · Cited by 43
Foxc2 Is a Common Mediator of Insulin and Transforming Growth Factor β Signaling to Regulate Plasminogen Activator Inhibitor Type I Gene Expression
Fujita, H., Kang, M., Eren, M., Gleaves, L. A., Vaughan, D. E., & Kume, T. (2006) · Circulation Research · doi:10.1161/01.res.0000207407.51752.3c · Cited by 41
The Fat Mouse: A Powerful Genetic Model to Study Elevated Plasminogen Activator Inhibitor 1 in Obesity/NIDDM
David, J. L., & Samad, F. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657606 · Cited by 41
The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM.
Samad, F., & Loskutoff, D. J. (1997) · PubMed · Cited by 38
Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNFalpha receptors to PAI-1 levels.
Bastelica, D., Mavri, A., Verdier, M., Berthet, B., Juhan-Vague, I., & Alessi, M. (2002) · PubMed · Cited by 38
Self-citation
Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans
van Loon, B. J. P., de Bart, A. C. W., Radder, J. K., Frölich, M., Kluft, C., & Meinders, A. E. (1990) · Fibrinolysis and Proteolysis · doi:10.1016/0268-9499(90)90373-r · Cited by 37
Hyperinsulinemia and hypofibrinolysis: Effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients
Lormeau, B., Aurousseau, M. H., Valensi, P. E., Pariès, J., & Attali, J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90281-x · Cited by 34
Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice
Lijnen, R. H. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0043 · Cited by 34
Induction of plasminogen activator inhibitor‐1 (PAI‐1) gene expression in adipocytes by thiazolidinediones
Ihara, H., Urano, T., Takada, A., & Loskutoff, D. J. (2001) · The FASEB Journal · doi:10.1096/fj.00-0570fje · Cited by 34
Relationships between Fibrinolytic and Inflammatory Parameters in Human Adipose Tissue: Strong Contribution of TNFα Receptors to PAI-1 Levels
Bastelica, D., Mavri, A., Verdier, M., Berthet, B., Juhan-Vague, I., & Alessi, M. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613241 · Cited by 31
Self-citation
Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study.
Folsom, A. R., Pankow, J. S., Williams, R. R., Evans, G. W., Province, M. A., & Eckfeldt, J. H. (1998) · PubMed · Cited by 29
15-Deoxy-prostaglandin J2 inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPARγ
Zhang, J., Fu, M., Zhao, L., & Chen, Y. E. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02401-4 · Cited by 27
Plasminogen-activator inhibitor-1 polymorphisms are associated with obesity and fat distribution in the Qu??bec Family Study: evidence of interactions with menopause
Bouchard, L., Mauriège, P., Vohl, M., Bouchard, C., & P??russe, L. (2005) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200512020-00006 · Cited by 26
Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians
Nagi, D. K., Tracy, R. P., & Pratley, R. E. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90242-5 · Cited by 25
Expression of FOXC2 in adipose and muscle and its association with whole body insulin sensitivity
Gregorio, G. B. D., Westergren, R., Enerbäck, S., Lu, T., & Kern, P. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00155.2004 · Cited by 22
Fibrinogen, Plasminogen Activator Inhibitor-1, and Carotid Intima-Media Wall Thickness in the NHLBI Family Heart Study
Pankow, J. S., Williams, R., Evans, G. R. D., Province, M. A., Eckfeldt, J. H., & Folsom, A. R. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614999 · Cited by 21
11β‐Hydroxysteroid dehydrogenase type 1‐driven cortisone reactivation regulates plasminogen activator inhibitor type 1 in adipose tissue of obese women
AYACHI, S. E., Paulmyer‐Lacroix, O., Verdier, M., Alessi, M., Dutour, A., & Grino, M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01811.x · Cited by 17
Self-citation
Tissue plasminogen activator in the bed nucleus of stria terminalis regulates acoustic startle
Matys, T., Pawlak, R., & Strickland, S. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.06.076 · Cited by 14
Increased plasminogen activator inhibitor‐1 levels in android obesity: correlation with oxidative stress
Ferroni, P., Guagnano, M. T., Manigrasso, M. R., Ciabattoni, G., & Davı̀, G. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01395.x · Cited by 13
Proposal of a novel diabetogenic mechanism involving the serpin PAI‐1
Griffiths, S. L., & Grainger, D. J. (2006) · BioEssays · doi:10.1002/bies.20418 · Cited by 12
To: J. Hoffstedt et al. (2002) The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity
Freeman, M. S., & Mansfield, M. W. (2002) · Diabetologia · doi:10.1007/s00125-002-0961-z · Cited by 10

Research works printed but not linked: 22

10.1161/circ.99.19.2496 · DOI
10.1161/circ.94.9.2057 · DOI
10.1161/circ.98.21.2241 · DOI
10.1161/circ.91.5.1432 · DOI
10.1161/atvb.18.1.84 · DOI
10.1161/atv91.13.2.8427853 · DOI
10.1161/circ.97.22.2213 · DOI
10.1161/atvb.21.8.1378 · DOI
10.1161/circ.93.1.106 · DOI
10.1161/atvb.22.1.173 · DOI
10.1161/atvb.16.3.368 · DOI
2005, Biochem Biophys Res Commun, 19, 30
1999, J Clin Endocrinol Metab, 84, 4097
10.1161/atvb.18.11.1679 · DOI
10.1161/res.85.2.208 · DOI
1990, Fibrinolysis, 4, 93
10.1161/hyp.32.6.965 · DOI
10.1161/hyp.37.5.1336 · DOI
2004, PLoS Biol, 2, 1893
10.1161/atv91.11.1.1670989 · DOI
Crandall DJ Quinet EM El Ayachi S Hreha AL Leik CE SavioDA Juhan-Vague I Alessi MC. Modulation of adipose tissue evelopment by pharmacologic inhibition of PAI-1. Arterioscler Thromb Vasc Biol . In press
10.1161/atvb.20.4.1150 · DOI

Sorted by citations

Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889
Retracted
Adipokines: The missing link between insulin resistance and obesity
Antuna-Puente, B., Fève, B., Fellahi, S., & Bastard, J. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.09.004 · Cited by 760
Pathophysiology of the metabolic syndrome
McCracken, E., Monaghan, M., & Sreenivasan, S. (2017) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2017.09.004 · Cited by 785
Hepatic insulin resistance, metabolic syndrome and cardiovascular disease
Meshkani, R., & Adeli, K. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.018 · Cited by 470

See all 390

Authors: Alessi, M.-C., & Juhan-Vague, I.
Affiliations: Inserm (FR)
From the Laboratory of Hematology, INSERM UMR 626, Faculty of Medicine, Marseilles, France.
ORCID: Alessi, Marie-Christine
Venue: Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2006-10
Volume: 26
Issue: 10
Pages: 2200-2207
ISSN: 1079-5642 (ISSN-L)
1524-4636
DOI: 10.1161/01.atv.0000242905.41404.68
OpenAlex: W2120559894
Cited by: 390
References: 124
Citations by year: 2026: 17 · 2025: 16 · 2024: 22 · 2023: 14 · 2022: 24 · 2021: 19 · 2020: 11 · 2019: 13 · 2018: 12 · 2017: 18 · 2016: 23 · 2015: 17 · 2014: 16 · 2013: 22 · 2012: 19
FWCI: 3.51
Type: journal article
Language: en
Open access: closed
Locations: Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
PubMed (publishedVersion)
Arteriosclerosis Thrombosis and Vascular Biology
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords: plasminogen activator inhibitor-1, metabolic syndrome, obesity, cardiovascular risk, atherothrombosis, insulin resistance, adipose tissue development, PAI-1 inhibitors
MeSH terms: Cardiovascular Diseases, Humans, Obesity, Plasminogen Activator Inhibitor 1, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks